Vertical: HealthcareBase Year: 2018
Market Size (2018)
$58.56B
Projected (2024)
$92.41B
CAGR (2016–2024)
8.0%
Key Players
15+
This report covers Cholic Acid Market with forecasts from 2016 to 2024. 15 key companies are profiled.
The Cholic Acid Market market is projected to grow at a CAGR of 8.0% from 2016 to 2024.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansCholic acid is a primary bile acid synthesized by the liver from cholesterol. The role of bile acids is to emulsify (breakdown into small particles) fats and thus promote the process of digestion. Cholic acid is primarily used as an intermediate for the production of ursodeoxycholic acid (UDCA), which is an active pharmaceutical ingredient (API) used for various indications like the dissolution of gall stones and treating and preventing liver diseases.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThis report applies a rigorous multi-stage research process combining primary interviews, secondary data sources, and bottom-up market modelling to ensure accuracy and completeness across all segments and geographies.
Base Year
2018
Historical Period
2016 – 2017
Forecast Period
2019 – 2024
Primary Interviews
150+
Historical data (2016–2018) and forecast period (2018–2024)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe global cholic acid market consists of a limited number of manufacturers and increasing competition in the market. Europe and Asia-Pacific are hubs for major companies that have been generating a relatively significant market share which has turned these regions into developed markets for the product. These companies have expanded their distribution units in various other regions as well. Moreover, there are other small- and medium-scale players that generate revenue from local markets.
Industria Chimica Emiliana SRL (Italy), New Zealand Pharmaceuticals Limited (New Zealand), Daewoong Bio Inc. (South Korea), Dipharma Francis SRL (Italy), and Suzhou Tianlu Biopharmaceuticals Co. Ltd (China) are the major player in the global cholic acid market.
Industria Chimica Emiliana SRL (Italy) is a leading player in the cholic acid market. The company, along with Prodotti Chimici e Alimentari SpA (part of the ICE SpA Group), accounts for the major production of cholic acid across the globe. The company focuses primarily on expanding the areas they are already strong in such as active pharmaceutical ingredients (APIs) and bacteriological products. The company focus on an inorganic growth strategy to maintain its leading position in the market. Moreover, it entered into an agreement with Shilpa Medical Ltd for manufacturing drugs and pharmaceutical products. The company offers dehydrocholic acid and ursodeoxycholic acid in the global market. It has a strong presence in Latin America, North America, Europe, and Asia.
New Zealand Pharmaceuticals Limited is (New Zealand) a key player operating in the cholic acid market. The company is providing innovative products by strengthening research and development capabilities. The company offers pharmaceutical intermediates and ingredients such as cholic acid, dehydrocholic acid, and deoxycholic acid. The company focuses on an organic growth strategy to increase its market share in the global market.
Daewoong Bio Inc. (South Korea) is one of the top producers of APIs in Asia and one of the major exporters of APIs in regions including North America, Europe, and Japan. The company is focusing on expanding its presence in western pharmaceutical markets. The company offers ursodeoxycholic acid in the global cholic acid market.
Dipharma Francis SRL (Italy) develops and offers a wide range of APIs in the market. The company has a strong research and development base that helps it to launch innovative products in the market. It has a strong presence in European countries.
Suzhou Tianlu Biopharmaceuticals Co. Ltd (China) is a well-known Asian company offering APIs in the global market. With an annual production capacity of over 230 tons, the company produces a wide range of API products. It offers a wide range of products with respect to cholic acid in the global market. Moreover, to meet the demand from its customers, the company has invested and established a pharmaceutical intermediate project with an annual production capacity of over 530 tons of cholic products in Dezhou, Shandong province. With this expansion, the company is expected to enhance its production capacity and also its annual revenue for cholic acid products.
Threat of New Entrants
The threat of new entrants is medium in the global cholic acid market. In Porter’s Five Forces Analysis, the ‘Threat of New Entrants’ refers to the threat that new competitors pose to existing competitors in an industry. A profitable industry will attract more competitors looking to achieve profits. As the number of entrants increases, the profitability of the present players in the industry subsequently decreases. The global cholic acid market has a medium threat of new entrants, threatening the existing players.
Bargaining Power of Suppliers
Bargaining power of suppliers in the global cholic acid market is medium. The bargaining power of suppliers estimates how easy it is for the suppliers to influence the prices of the final products made by innovators. Businesses must obtain the necessary resources that they need from the resource suppliers to carry out their activities.
In the global cholic acid industry, the number of suppliers is comparatively less than the number of firms operating in the sector, and only a few of them have a large hold on the cholic acid market. The recessionary pressures have reduced the price of many components and raw materials due to downward demand trends. Moreover, the switching cost of these suppliers is also medium as the suppliers tend to enter long-term associations with the manufacturers. Threat of Substitutes
The threat of substitutes in the global cholic acid market is medium to low. The substitute to the cholic acid can only be in the form of large molecules. Buyer propensity to substitute is low due to the lesser availability of substitutes in this market. In addition, the high degree of switching cost minimizes the threat of substitutes.
Bargaining Power of Buyers
The bargaining power of the buyer is considered to have a low impact on the industry. The bargaining power of the buyers evaluates how easy it is for the buyers to affect the price of pharmaceutical products. There is a low number of players with capabilities to manufacture high-end drugs.
Also, the high differential advantage of the cholic acid market coupled with low or poor existing substitutes for high tech products makes the position of the manufacturers strong.
Intensity of Rivalry
The degree of competition in the global cholic acid market is high. The moderate degree of product differentiation among existing players increases the intensity of rivalry in the market. The intensity of competitive rivalry evaluates the capability and the level of rivalry among competitors in the market. It also refers to the extent to which firms within an industry put pressure on one another and limit each other’s profit potential. Rivalry among industry players can affect industry profits through downward pressure on prices, increased innovation, increased advertising, and increased service/product improvements, among others.
Market estimates by geography (2024)
InsightEurope leads with $35.14B by 2024, while Americas is projected to grow fastest at a 8.6% CAGR.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription Plans| REGION | 2016 | 2018 | 2024 | CAGR | SHARE |
|---|---|---|---|---|---|
| Asia Pacific | $14.98B | $20.78B | $28.50B | 8.4% | 31% |
| Europe | $19.88B | $26.59B | $35.14B | 7.4% | 38% |
| Middle East and Africa | $1.17B | $1.61B | $2.19B | 8.1% | 2% |
| Americas | $13.72B | $19.20B | $26.58B | 8.6% | 29% |
| Total | $49.74B | $68.18B | $92.41B | 8.0% | 100% |
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSee plans for professionals or small and medium businesses.
Analytical insights on Cholic Acid Market covering market dynamics, competitive landscape, and strategic outlook.
The Cholic Acid Market market is projected to reach $92.41B by 2024, growing at 8.0% CAGR.
Gallstones are deposits of cholesterol and other digestive fluids that form in the gallbladder. Cholic acid is used as an active pharmaceutical ingredient in manufacturing medications for dissolution of gallstones. Apart from treating gallstones, cholic acid is also used in treating bile acid synthesis disorders and Zellweger Spectrum Disorders.
According to the American Cancer Society, gallstones are one of the major factors contributing to gallbladder cancer. The cases of gallbladder cancer diagnosed are increasing globally. For instance, according to a study by the World Cancer Research Fund (WCRF) International, around 2,20,000 new cases of gallbladder cancer were diagnosed globally in the year 2018.
This increase in the cases of gallbladder cancer reflects the probable increase in the increased prevalence of one of its factors, bile stones. Owing to this increase, the demand for cholic acid, which is used as an active pharmaceutical ingredient (API), is expected to increase and thus boost the global cholic acid market growth.
The European region is leading the manufacturing of cholic acid globally followed by the Americas and Asia-Pacific. The drug manufacturers in the Middle Eastern and African region mainly rely on import for meeting their requirement of cholic acid. Around 80% of the cholic acid is manufactured in other regions of the world, and only 20% is manufactured in the Middle East and Africa. This provides an opportunity for manufacturers to establish new manufacturing facilities for cholic acid.
The exporters of cholic acid are abiding by the good manufacturing practice (GMP) in the European region, whereas the FDA is regulating the quality assurance in the US and other regions. The regulatory compliance is considered to be the primary hurdle challenging the cholic acid (API) market at every point.
Besides, the Indian cholic acid manufacturers are investing to comply with the US FDA regulations for obtaining contracts from the US-based companies. They are also filing the drug master file (DMF) applications in the US. Thus, it has been observed that Indian cholic acid manufacturers are strengthening their presence in the global cholic acid market. Although these regulations are serving to improve and maintain the quality of drugs, they are also curbing the growth of the cholic acid (API) manufacturing market, especially in developing regions of Asia-Pacific.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 113 companies operating in the Cholic Acid Market market, including revenue, employee count, and market positioning where available.
Showing 113 of 113 companies
Company Headquarters: Tokyo, Japan Founded: 1939 Workforce: ~10,476 Company Working: Showa Denko KK is a chemical company that engages in the manufacturing and marketing of a wide range of petrochemicals, chemicals, electronics, inorganic chemicals, aluminum, and other products. The company, along with its affiliates and subsidiaries, operates in North America, Europe, and Asia. It provides products and services that are useful and exceed customer expectation.
Company Headquarters: Germany Founded: 1947 Workforce: ~800 Company Working: PharmaZell GmbH develops and manufactures APIs for pharmaceutical purposes. It provides services for the development of formulations and other pharmaceutical intermediates and produces amino acids. The company markets its products worldwide.
Company Headquarters: China Founded: 1984 Workforce: ~260 Company Working: Panjin Hengchanglong Pharmaceutical is located in China. It offers 25 major pharmaceutical products and more than 100 kinds of traditional Chinese medicinal foods. The company is primarily involved in manufacturing tablets; hard capsules; pills such as water-honeyed pills and concentrated pills; APIs; tea-containing products; and herbal tea.
Company Headquarters: Palmerston North, New Zealand Founded: 1971 Workforce: ~250 Company Working: New Zealand Pharmaceuticals Limited, manufactures pharmaceutical ingredients and diagnostic products for pharmaceutical and biotechnology companies. The company extracts and purifies biochemicals from the by-products of the New Zealand meat processing industry. It is one of the major manufacturers and suppliers of pharmaceutical products in the market. It also manufactures pharmaceutical ingredients, pharmaceutical intermediates, microbiological media, fermentation ingredients, dietary supplements, and cosmetic ingredients.
Company Headquarters: Alhama de Murcia, Murcia, Spain Founded: 1991 Workforce: ~200 Company Working: Kinsy SL is an independent chemical company headquartered in Spain. The company has a strong emphasis on the development and manufacturing of key APIs under the CGMP guidelines and manufacturing fine chemicals. The company’s primary focus is the development and synthesis of fine chemicals and pharmaceutical intermediates.
Company Headquarters: Italy Founded: 2005 Workforce: ~200 Company Working: Istituto Biologico Chemioterapico SpA is one of the leading organizations that manufacture APIs. It manufactures APIs, pharmaceutical intermediates, and others.
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
Market Size (USD Mn)
